Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Thiothixene
Drug ID BADD_D02204
Description A thioxanthine used as an antipsychotic agent. Its effects are similar to the phenothiazine antipsychotics.
Indications and Usage For the management of schizophrenia.
Marketing Status approved
ATC Code N05AF04
DrugBank ID DB01623
KEGG ID D00374
MeSH ID D013888
PubChem ID 5454
TTD Drug ID D0E0LQ
NDC Product Code 51407-275; 51407-277; 0378-5010; 51079-589; 0378-2002; 51407-276; 60219-1674; 60219-1675; 51079-588; 70954-014; 70954-015; 48954-575; 51407-278; 60219-1673; 0378-3005; 70954-016; 70954-017; 60219-1676; 70518-2594; 58159-042; 0378-1001; 53808-1129; 70518-2340; 70518-3147
UNII 7318FJ13YJ
Synonyms Thiothixene | Tiotixene | Navane
Chemical Information
Molecular Formula C23H29N3O2S2
CAS Registry Number 5591-45-7
SMILES CN1CCN(CC1)CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperprolactinaemia05.03.01.002--Not Available
Hyperpyrexia08.05.02.002--Not Available
Hyperreflexia17.02.01.002--Not Available
Hypersensitivity10.01.03.003--
Hypoglycaemia05.06.03.001; 14.06.03.001--
Hypotension24.06.03.002--
Ileus paralytic07.02.05.001--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Jaundice09.01.01.004; 01.06.04.004; 23.03.03.030--Not Available
Leukocytosis01.02.01.002--
Leukopenia01.02.02.001--Not Available
Loss of consciousness17.02.04.004--Not Available
Mastication disorder17.05.03.006; 07.01.06.016; 15.03.05.022--Not Available
Menstruation irregular21.01.01.005; 05.05.01.008--
Miosis17.02.11.002; 06.05.03.003--Not Available
Muscle spasms15.05.03.004--
Mydriasis17.02.11.003; 06.05.03.004--Not Available
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Neuroleptic malignant syndrome15.05.04.015; 17.05.02.003; 12.03.01.003; 08.05.01.005--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Pancytopenia01.03.03.003--Not Available
Parkinsonism17.01.05.003--Not Available
Photosensitivity reaction23.03.09.003--
Polydipsia14.05.02.001; 05.03.03.002--Not Available
Pregnancy test false positive13.10.05.003--Not Available
Protrusion tongue17.02.05.037; 07.14.02.002--Not Available
Pruritus23.03.12.001--
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene